Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2013-12-09
Original market date: See footnote 1
2013-12-09
Product name:
UVADEX
Description:
TO BE ADMINSTERED VIA THE UVAR XTS OR THERAKOS CELLEX PHOTOPHERESIS SYSTEMS
DIN:
02406233
Product Monograph/Veterinary Labelling:
Date:
2021-08-30
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
THERAKOS LLC
102
1170 Us 22 E
Bridgewater
New Jersey
United States
08807
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Extracorporeal
Number of active ingredient(s):
1
Schedule(s):
Prescription
American Hospital Formulary Service (AHFS): See footnote 3
84:50.06
Anatomical Therapeutic Chemical (ATC): See footnote 4
D05BA02 METHOXALEN, SYSTEMIC
Active ingredient group (AIG) number:See footnote5
0107802003
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| METHOXSALEN | 20 MCG / ML |